StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE) Announces Top-Line Results from Study of CHANTIX/CHAMPIX (varenicline) in Adolescent Smokers
March 23, 2018 8:01 AM
Pfizer Inc. (NYSE: PFE) announced today results from a Phase 4 study evaluating the efficacy and safety of CHANTIX®/CHAMPIX® (varenicline) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Pfizer Reports Top-Line Results from a Study of CHANTIX®/CHAMPIX® (varenicline) in Adolescent Smokers
March 23, 2018 8:00 AM
ViiV Healthcare Gains CHMP Positive Opinion for Juluca in Europe (GSK) (PFE)
March 23, 2018 7:28 AM
GSK pulls out of $20 billion race for Pfizer consumer assets
March 23, 2018 4:04 AM
Back to the drawing board for Reckitt after dropping Pfizer bid
March 22, 2018 9:31 AM
European shares suffer as trade jitters, weak data weigh
March 22, 2018 4:52 AM
GSK advances in Pfizer consumer health auction as Reckitt quits
March 21, 2018 4:30 PM
Reckitt Benckiser Ends Pfizer (PFE) Talks on Consumer Healthcare Unit - Bloomberg
March 21, 2018 4:13 PM
GlaxoSmithKline prescribes commercial reboot for pharma division
March 21, 2018 3:37 AM
